Ernexa Therapeutics Inc. Operating Lease Cost
Ernexa Therapeutics Inc. (ERNA) reported Operating Lease Cost of $43.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Ernexa Therapeutics Inc. operating lease, cost for the quarter ending 2026-06-30 was $43.00K, a 36.76% decline year-over-year.
- Ernexa Therapeutics Inc. operating lease, cost for the quarter ending 2026-03-31 was $89.00K, a 32.84% increase year-over-year.
- Ernexa Therapeutics Inc. operating lease, cost for the quarter ending 2025-12-31 was $69.00K, a 2.99% increase year-over-year.
- Ernexa Therapeutics Inc. operating lease, cost for the quarter ending 2025-09-30 was $67.00K, a 93.96% decline year-over-year.
- Ernexa Therapeutics Inc. operating lease, cost for fiscal 2025 was $271.00K, a 93.91% decline from fiscal 2024.
- Ernexa Therapeutics Inc. operating lease, cost for fiscal 2024 was $4.45M, a 30.83% increase from fiscal 2023.
- Ernexa Therapeutics Inc. operating lease, cost for fiscal 2023 was $3.40M, a 471.26% increase from fiscal 2022.
- Ernexa Therapeutics Inc. operating lease, cost for fiscal 2022 was $595.00K, a 13.52% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.00K 10-Q · filed 2026-08-06 | $132.00K 10-Q · filed 2026-08-06 | $201.00K derived: sum of 3 quarters · filed 2026-08-06 | $268.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $89.00K 10-Q · filed 2026-05-11 | $158.00K derived: sum of 2 quarters · filed 2026-05-11 | $225.00K derived: sum of 3 quarters · filed 2026-05-11 | $293.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $136.00K derived: sum of 2 quarters · filed 2026-03-13 | $204.00K derived: sum of 3 quarters · filed 2026-08-06 | $271.00K 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $67.00K 10-Q · filed 2025-11-07 | $135.00K derived: sum of 2 quarters · filed 2026-08-06 | $202.00K 10-Q · filed 2025-11-07 | $269.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $68.00K 10-Q · filed 2026-08-06 | $135.00K 10-Q · filed 2026-08-06 | $202.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.31M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $67.00K 10-Q · filed 2026-05-11 | $134.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.24M derived: sum of 3 quarters · filed 2026-05-11 | $2.88M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.18M derived: sum of 2 quarters · filed 2026-03-13 | $2.81M derived: sum of 3 quarters · filed 2026-03-13 | $4.45M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $1.11M 10-Q · filed 2025-11-07 | $2.74M derived: sum of 2 quarters · filed 2025-11-07 | $4.38M 10-Q · filed 2025-11-07 | $6.02M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $1.63M 10-Q · filed 2025-08-13 | $3.27M 10-Q · filed 2025-08-13 | $4.91M derived: sum of 3 quarters · filed 2025-08-13 | $6.53M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $1.64M 10-Q · filed 2025-05-07 | $3.28M derived: sum of 2 quarters · filed 2025-05-07 | $4.90M derived: sum of 3 quarters · filed 2025-05-07 | $4.97M derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.26M derived: sum of 2 quarters · filed 2025-03-12 | $3.33M derived: sum of 3 quarters · filed 2025-03-12 | $3.40M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $1.62M 10-Q · filed 2024-11-12 | $1.69M derived: sum of 2 quarters · filed 2024-11-12 | $1.76M 10-Q · filed 2024-11-12 | $1.88M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $67.00K 10-Q · filed 2024-08-13 | $135.00K 10-Q · filed 2024-08-13 | $254.00K derived: sum of 3 quarters · filed 2024-08-13 | $397.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $68.00K 10-Q · filed 2024-05-14 | $187.00K derived: sum of 2 quarters · filed 2024-05-14 | $330.00K derived: sum of 3 quarters · filed 2024-05-14 | $476.00K derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $262.00K derived: sum of 2 quarters · filed 2024-03-14 | $408.00K derived: sum of 3 quarters · filed 2024-03-14 | $595.00K 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $143.00K 10-Q · filed 2023-11-13 | $289.00K derived: sum of 2 quarters · filed 2023-11-13 | $476.00K 10-Q · filed 2023-11-13 | $662.00K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $146.00K 10-Q · filed 2023-08-11 | $333.00K 10-Q · filed 2023-08-11 | $519.00K derived: sum of 3 quarters · filed 2023-08-11 | $706.00K derived: sum of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | $186.00K 10-Q · filed 2023-05-11 | $373.00K derived: sum of 2 quarters · filed 2023-05-11 | $560.00K derived: sum of 3 quarters · filed 2023-05-11 | $724.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $374.00K derived: sum of 2 quarters · filed 2023-03-20 | $538.00K derived: sum of 3 quarters · filed 2023-03-20 | $688.00K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $187.00K 10-Q · filed 2022-11-14 | $187.50K 10-Q · filed 2021-11-12 | $351.00K derived: sum of 2 quarters · filed 2022-11-14 | $501.00K 10-Q · filed 2022-11-14 | $501.10K 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $164.00K 10-Q · filed 2022-08-11 | $163.75K 10-Q · filed 2021-08-13 | $315.00K 10-Q · filed 2022-08-11 | $314.62K 10-Q · filed 2021-08-13 | |||
| 2021-03-31 | $151.00K 10-Q · filed 2022-07-01 | $150.87K 10-Q · filed 2021-05-17 | |||||
| 2020-12-31 | $591.00K 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |